Vor Biopharma Inc. (VOR) shareholders
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$19.42+0.10 (+0.52%)
Close on Nov 13, 2026Market cap $1.19BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.3%
49M of 61M shares
Institutional holders
102
39 new, 17 sold out
Net institutional buying
9M
In Q2 2026
Insider trades, 12 months
0 buys · 16 sales
Net sold $49.42M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (19.90%), Peter Kolchinsky (19.90%) and 1 more | 12,937,855 | 19.90% | 13D (active) amendment | Jul 16, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (19.90%), Rajeev Shah (19.90%) and 1 more | 12,896,519 | 19.90% | 13D (active) amendment | Apr 20, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (19.90%), Rajeev Shah (19.90%) and 1 more | 12,739,024 | 19.90% | 13D (active) amendment | Apr 14, 2026 |
| ForGrowth III PA B.V. Joint filing with Forbion Growth Opportunities Fund III Cooperatief U.A. (9.99%), Forbion Growth III Management B.V. (9.99%) | 10,237,714 | 9.99% | 13D (active) | Dec 18, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (10.70%) | 6,318,525 | 10.70% | 13G (passive) amendment | Sep 30, 2026 |
| VHCP Co-Investment Holdings III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), Venrock Healthcare Capital Partners EG, L.P. (9.90%) and 4 more | 5,676,370 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Chen Yu Joint filing with TCG Crossover GP II, LLC (5.20%), TCG Crossover Fund II, L.P. (5.20%) and 2 more | 5,673,078 | 10.50% | 13G (passive) | Mar 30, 2026 |
| Nimish Shah Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 5,083,877 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Verve Capital Limited | 3,410,892 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,099,259 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.50%) | 2,526,170 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| Fhmlsp, L.P. Joint filing with Frazier Life Sciences Public Fund, L.P. (5.80%), Fhmlsp, L.L.C. (5.80%) | 2,258,001 | 5.80% | 13G (passive) | Dec 18, 2025 |
| Venrock Healthcare Capital Partners EG, L.P. Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 2,216,075 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Reid Hoffman Joint filing with Reprogrammed Interchange LLC (18.60%) | 1,278,118 | 18.60% | 13D (active) amendment | Oct 14, 2025 |
| Great Point Partners, LLC Joint filing with Dr. Jeffrey R. Jay, M.D. (5.63%), Ms. Lillian Nordahl (5.63%) | 1,234,486 | 5.63% | 13G (passive) | Dec 10, 2025 |
| Reprogrammed Interchange LLC Joint filing with Reid Hoffman (17.60%) | 1,204,442 | 17.60% | 13D (active) amendment | Oct 15, 2025 |
| VHCP Management III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 760,699 | 9.90% | 13G (passive) | Sep 18, 2025 |
| Qiming GP VIII-HC, LLC Joint filing with Qiming Venture Partners VIII-HC, L.P. (5.44%) | 496,272 | 5.44% | 13G (passive) | Sep 18, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VOR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 5,673,078 | 9.23% | $104.44M | – | 2.51% |
| FMR LLC | 4,932,149 | 8.03% | $90.80M | +3,392,479 | 0.00% |
| Fcpm Iii Services B.V. | 4,117,354 | 6.70% | $75.80M | – | 10.10% |
| BlackRock, Inc. | 3,468,107 | 5.65% | $63.85M | +2,673,348 | 0.00% |
| VR Adviser, LLC | 3,041,719 | 4.95% | $56.00M | – | 1.70% |
| State Street Corp | 2,616,336 | 4.26% | $48.17M | +1,497,878 | 0.00% |
| Frazier Life Sciences Management, L.P. | 2,543,939 | 4.14% | $46.83M | – | 1.02% |
| Ra Capital Management, L.P. | 2,402,095 | 3.91% | $44.22M | −3,002,903 | 0.38% |
| Vanguard Capital Management LLC | 2,084,328 | 3.39% | $38.37M | +651,048 | 0.00% |
| Caligan Partners LP | 1,925,066 | 3.13% | $35.44M | – | 1.67% |
| Paradigm Biocapital Advisors LP | 1,750,000 | 2.85% | $32.22M | – | 0.60% |
| Great Point Partners LLC | 1,700,000 | 2.77% | $31.30M | −50,000 | 5.91% |
| Nantahala Capital Management, LLC | 1,690,000 | 2.75% | $31.11M | New | 0.52% |
| Geode Capital Management, LLC | 1,062,469 | 1.73% | $19.56M | +719,896 | 0.00% |
| NEXTBio Capital Management LP | 889,164 | 1.45% | $16.37M | −110,803 | 7.53% |
| ADAR1 Capital Management, LLC | 680,626 | 1.11% | $12.53M | New | 0.57% |
| Logos Global Management LP | 650,000 | 1.06% | $11.97M | −100,000 | 0.52% |
| Rosalind Advisors, Inc. | 648,600 | 1.06% | $11.94M | −51,400 | 4.44% |
| Nan Fung Trinity (Hk) Ltd | 646,550 | 1.05% | $11.90M | New | 1.18% |
| Braidwell LP | 573,104 | 0.93% | $10.55M | +106,330 | 0.39% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 49M | 80.3% | 39 / 35 | 19 / 17 | 15M | 6M |
| Q1 2026 | 80 | 40M | 65.8% | 35 / 26 | 9 / 9 | 18M | 2M |
| Q4 2025 | 55 | 26M | 41.6% | 28 / 19 | 2 / 10 | 22M | 0M |
| Q3 2025 | 37 | 4M | 6.1% | 12 / 9 | 15 / 10 | 1M | 0M |
| Q2 2025 | 35 | 3M | 4.6% | 8 / 8 | 10 / 19 | 0M | 0M |
| Q1 2025 | 46 | 3M | 4.9% | 10 / 9 | 18 / 16 | 0M | 0M |
| Q4 2024 | 52 | 3M | 5.0% | 14 / 7 | 15 / 16 | 1M | 0M |
| Q3 2024 | 54 | 2M | 3.9% | 10 / 8 | 19 / 26 | 0M | 1M |
| Q2 2024 | 71 | 3M | 4.4% | 23 / 16 | 20 / 21 | 0M | 0M |
| Q1 2024 | 69 | 3M | 4.8% | 12 / 20 | 19 / 2 | 0M | 0M |
| Q4 2023 | 60 | 3M | 4.9% | 7 / 22 | 13 / 5 | 0M | 0M |
| Q3 2023 | 59 | 3M | 4.9% | 2 / 17 | 17 / 14 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
82 funds held VOR in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VOR | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,756,293 | 2.86% | $32.33M | 0.30% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,550,885 | 2.52% | $28.55M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,270,144 | 2.07% | $26.86M | 0.31% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,185,725 | 1.93% | $17.75M | 0.34% | May 31, 2026 |
| iShares Russell 2000 ETF | 951,914 | 1.55% | $17.52M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 650,678 | 1.06% | $13.76M | 0.30% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 590,012 | 0.96% | $12.48M | 0.17% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 492,147 | 0.80% | $9.06M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 446,413 | 0.73% | $9.44M | 0.03% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 402,327 | 0.65% | $8.51M | 0.18% | Jul 31, 2026 |
| Fidelity Small Cap Discovery Fund | 347,860 | 0.57% | $7.36M | 0.32% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 343,954 | 0.56% | $7.27M | 0.33% | Jul 31, 2026 |
| Fidelity Series Small Cap Discovery Fund | 298,000 | 0.49% | $6.30M | 0.32% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 238,381 | 0.39% | $4.39M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 154,727 | 0.25% | $2.32M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jean-Paul Kress | CEO and Chairman, Director | – | – | Dec 9, 2025 |
| Robert Ang | PRESIDENT AND CEO, Director | 911,318 | 1.48% | May 7, 2025 |
| Jeremy Brett Sokolove | Chief Medical Officer | 25,983 | 0.04% | Nov 4, 2026 |
| Sandesh Mahatme | CFO | 0 | – | Dec 9, 2025 |
| Qing Che Zuraw | Chief Development Officer | 937,080 | 1.53% | Dec 9, 2025 |
| Tirtha Chakraborty | Chief Sci Off & Head Tech Ops | 217,416 | 0.35% | May 7, 2025 |
| Han Wook Choi | Chief Financial Officer | 51,280 | 0.08% | May 2, 2025 |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | 126,625 | 0.21% | Feb 18, 2025 |
| David Zaccardelli | Director | – | – | Jul 9, 2026 |
| Alexander Cumbo | Director | – | – | Jun 12, 2026 |
| Fouad Namouni | Director | – | – | Jun 12, 2026 |
| Michel Detheux | Director | – | – | Jun 12, 2026 |
| Wouter Joustra | Director | – | – | Jun 12, 2026 |
| Andrew David Levin | Director | – | – | Jun 12, 2026 |
| Erez Kalir | Director | – | – | Jun 12, 2026 |
| Daniella Beckman | Director | – | – | Jun 12, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 1,401,226 | 2.28% | Oct 22, 2025 |
| Sarah Burgess Reed | Director | – | – | Sep 10, 2025 |
| Matthew R. Patterson | Director | 41,196 | 0.07% | May 23, 2025 |
| Sven Ante Lundberg | Director | 29,432 | 0.05% | May 23, 2025 |
| David Charles Lubner | Director | – | – | May 23, 2025 |
| Joshua Resnick | Director | – | – | May 23, 2025 |
| Rajeev M. Shah | 10% owner | 4,501,882 | 7.33% | Oct 5, 2026 |
| Peter Kolchinsky | 10% owner | 4,607,244 | 7.50% | Oct 5, 2026 |
| Ra Capital Management, L.P. | 10% owner | 500 | 0.00% | Oct 5, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 1,500 | 0.00% | Oct 5, 2026 |
| TCG Crossover GP II, LLC | 10% owner | – | – | Apr 1, 2026 |
| TCG Crossover Fund II, L.P. | 10% owner | – | – | Apr 1, 2026 |
| TCG Crossover GP III, LLC | 10% owner | – | – | Apr 1, 2026 |
| TCG Crossover Fund III, L.P. | 10% owner | 2,836,539 | 4.62% | Apr 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeremy Brett Sokolove Chief Medical Officer | Nov 2, 2026 | Tax withholding | −1,917 | $19.25 | $36.90K | 25,983 |
| Ra Capital Management, L.P. 10% owner | Oct 2, 2026 | Option exercise | +500 | $12.80 | $6.40K | 500 |
| Capital Healthcare Fund LP RA 10% owner | Aug 24, 2026 | Option exercise | +1,500 | $3.74 | $5.61K | 1,500 |
| Rajeev M. Shah 10% owner | Jul 16, 2026 | Sale | −213 | $19.75 | $4.21K | 4,501,882 |
| Rajeev M. Shah 10% owner | Jul 16, 2026 | Option exercise | +2,100,000 | – | – | 4,502,095 |
| Rajeev M. Shah Director, 10% owner | Apr 22, 2026 | Sale | −165,150 | $15.77 | $2.60M | 2,402,095 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 20, 2026 | Sale | −171,963 | $15.77 | $2.71M | 2,567,245 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 17, 2026 | Sale | −458,411 | $16.28 | $7.46M | 2,739,208 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 15, 2026 | Sale | −53,644 | $16.01 | $858.84K | 3,197,619 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 14, 2026 | Sale | −153,735 | $15.97 | $2.46M | 3,251,263 |
| Ra Capital Management, L.P. Director, 10% owner | Apr 13, 2026 | Sale | −530,610 | $16.15 | $8.57M | 3,404,998 |
| Rajeev M. Shah Director, 10% owner | Apr 10, 2026 | Sale | −828 | $15.75 | $13.04K | 3,935,608 |
| Rajeev M. Shah Director, 10% owner | Apr 9, 2026 | Sale | −135,201 | $16.59 | $2.24M | 3,936,436 |
| Rajeev M. Shah Director, 10% owner | Apr 8, 2026 | Sale | −353,242 | $16.32 | $5.76M | 4,202,499 |
| Rajeev M. Shah Director, 10% owner | Apr 8, 2026 | Sale | −130,862 | $16.91 | $2.21M | 4,071,637 |
| Peter Kolchinsky Director, 10% owner | Apr 6, 2026 | Sale | −537,754 | $16.51 | $8.88M | 4,607,244 |
| Peter Kolchinsky Director, 10% owner | Apr 6, 2026 | Sale | −6,775 | $18.50 | $125.34K | 4,555,741 |
| Peter Kolchinsky Director, 10% owner | Apr 6, 2026 | Sale | −44,728 | $17.31 | $774.24K | 4,562,516 |
| Peter Kolchinsky Director, 10% owner | Apr 2, 2026 | Sale | −258,475 | $18.23 | $4.71M | 5,146,523 |
| Peter Kolchinsky Director, 10% owner | Apr 2, 2026 | Sale | −1,525 | $19.06 | $29.07K | 5,144,998 |
| Ra Capital Management, L.P. Director, 10% owner | Dec 18, 2025 | Award | −4,625,346 | $10.81 | $50.00M | 5,404,998 |
| Sandesh Mahatme CFO | Dec 5, 2025 | Returned to company | −694,137 | – | – | 0 |
| Peter Kolchinsky Director, 10% owner | Oct 30, 2025 | Sale | −24,579 | $25.12 | $617.42K | 779,652 |
| Peter Kolchinsky Director, 10% owner | Oct 29, 2025 | Sale | −251,518 | $25.22 | $6.34M | 804,231 |
| Peter Kolchinsky Director, 10% owner | Oct 28, 2025 | Sale | −87,828 | $27.10 | $2.38M | 1,092,232 |
| Peter Kolchinsky Director, 10% owner | Oct 28, 2025 | Sale | −36,483 | $28.18 | $1.03M | 1,055,749 |
| Ra Capital Management, L.P. Director, 10% owner | Oct 27, 2025 | Sale | −90,941 | $28.12 | $2.56M | 1,180,060 |
| Ra Capital Management, L.P. Director, 10% owner | Oct 24, 2025 | Sale | −53,345 | $28.01 | $1.49M | 1,271,001 |
| Ra Capital Management, L.P. Director, 10% owner | Oct 23, 2025 | Sale | −76,880 | $28.01 | $2.15M | 1,324,346 |
| RA Capital Nexus Fund, L.P. Director | Oct 21, 2025 | Sale | −25,027 | $28.11 | $703.51K | 1,401,226 |
| Interchange LLC Reprogrammed 10% owner | Oct 21, 2025 | Sale | −200 | $30.08 | $6.02K | 1,166,909 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −6,553 | $30.12 | $197.38K | 1,426,253 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −1,287 | $30.12 | $38.76K | 0 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −70,366 | $29.63 | $2.08M | 1,432,806 |
| RA Capital Nexus Fund, L.P. Director | Oct 20, 2025 | Sale | −13,817 | $29.63 | $409.40K | 1,287 |
| Interchange LLC Reprogrammed 10% owner | Oct 20, 2025 | Sale | −11,616 | $30.05 | $349.06K | 1,167,109 |
| Interchange LLC Reprogrammed 10% owner | Oct 17, 2025 | Sale | −24,689 | $30.22 | $746.10K | 1,179,753 |
| Interchange LLC Reprogrammed 10% owner | Oct 17, 2025 | Sale | −1,028 | $31.00 | $31.87K | 1,178,725 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −174,594 | $29.12 | $5.08M | 1,546,621 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −2,492 | $31.00 | $77.25K | 15,104 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −12,691 | $31.00 | $393.42K | 1,503,172 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −6,040 | $30.28 | $182.89K | 17,596 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −30,758 | $30.28 | $931.35K | 1,515,863 |
| Rajeev M. Shah Director, 10% owner | Oct 17, 2025 | Sale | −34,284 | $29.12 | $998.35K | 23,636 |
| Interchange LLC Reprogrammed 10% owner | Oct 16, 2025 | Sale | −2,021 | $30.45 | $61.54K | 1,204,442 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −111,041 | $29.32 | $3.26M | 1,737,061 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −21,804 | $29.32 | $639.29K | 61,032 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −15,826 | $30.36 | $480.48K | 1,721,235 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −3,108 | $30.36 | $94.36K | 57,924 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −20 | $31.35 | $627 | 1,721,215 |
| Rajeev M. Shah Director, 10% owner | Oct 16, 2025 | Sale | −4 | $31.35 | $125 | 57,920 |
| Interchange LLC Reprogrammed 10% owner | Oct 15, 2025 | Sale | −14,851 | $31.05 | $461.12K | 1,263,267 |
| Interchange LLC Reprogrammed 10% owner | Oct 15, 2025 | Sale | −48,910 | $32.05 | $1.57M | 1,214,357 |
| Interchange LLC Reprogrammed 10% owner | Oct 15, 2025 | Sale | −7,894 | $32.77 | $258.69K | 1,206,463 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −234 | $31.17 | $7.29K | 1,848,102 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −46 | $31.17 | $1.43K | 82,836 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −42,699 | $30.55 | $1.30M | 1,848,336 |
| Rajeev M. Shah Director, 10% owner | Oct 15, 2025 | Sale | −8,384 | $30.55 | $256.13K | 82,882 |
| Interchange LLC Reprogrammed 10% owner | Oct 14, 2025 | Sale | −33,668 | $30.32 | $1.02M | 1,278,118 |
| Interchange LLC Reprogrammed 10% owner | Oct 13, 2025 | Sale | −19,672 | $32.36 | $636.59K | 1,314,120 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
12.22%
8M shares short
Days to cover
9.9
At 1M shares a day
Change since last report
+0.8%
From 7M shares
Short volume, 20 days
50.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vor Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,267 shares on Oct 6, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 20, 2025 | 76,919 | $2.26M | Oct 20, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 20, 2025 | 15,104 | $444.51K | Oct 20, 2025 | Private Financing |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 17, 2025 | 218,043 | $6.32M | Oct 17, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 17, 2025 | 42,816 | $1.24M | Oct 17, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 16, 2025 | 24,916 | $724.06K | Oct 16, 2025 | Private Financing |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 16, 2025 | 126,887 | $3.69M | Oct 16, 2025 | Private Financing |
| RA Capital Nexus Fund, L.P. Director, 10% Stockholder | Oct 15, 2025 | 8,430 | $254.75K | Oct 15, 2025 | Private Financing |
| Capital Healthcare Fund LP RA Director, 10% Stockholder | Oct 15, 2025 | 42,933 | $1.30M | Oct 15, 2025 | Private Financing |
| Interchange LLC Reprogrammed 10% Stockholder | Sep 3, 2025 | 23,000,000 | $46.12M | Sep 3, 2025 | Private Placement |
| Robert Ang Officer, Director | Aug 11, 2025 | 18,382 | $36.41K | Aug 11, 2025 | Restricted Stock |
| Sven Ante Lundberg Director | Aug 4, 2025 | 29,432 | $61.59K | Aug 4, 2025 | Exercised Shares |
| Robert Ang Officer, Director | Jul 16, 2025 | 197,937 | $415.39K | Jul 16, 2025 | Exercised Shares |
| Robert Ang Officer, Director | Jul 15, 2025 | 214,135 | $520.59K | Jul 15, 2025 | Exercised Shares |
| Robert Ang Officer, Director | Jul 10, 2025 | 596,885 | $1.39M | Jul 10, 2025 | Restricted Stock |
| Robert Ang Officer, Director | Jul 2, 2025 | 44,936 | $80.44K | Jul 2, 2025 | Restricted Stock |
See a number that looks wrong?